These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17237628)

  • 1. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
    Jun EJ; Han JY; Sun HS
    Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
    Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
    J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
    Yuan BJ; Liu ZZ; Ding XR; Zou JM
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients.
    Lapinski TW; Kowalczuk O; Prokopowicz D; Chyczewski L
    World J Gastroenterol; 2004 Dec; 10(24):3650-3. PubMed ID: 15534924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of the sFas/sFasL system in psoriatic patients.
    Myśliwiec H; Baran A; Myśliwiec P; Górska M; Flisiak I
    Adv Med Sci; 2015 Mar; 60(1):64-8. PubMed ID: 25437350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
    Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of HBV-DNA, sFas and sFasL among healthy HBsAg carriers in period of three years.
    Lapiński TW; Kovalczuk O; Flisiak R; Pancewicz J
    Adv Med Sci; 2006; 51():46-50. PubMed ID: 17357276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble fas antigen and soluble fas ligand in intrauterine growth restriction.
    Briana DD; Baka S; Boutsikou M; Liosi S; Vraila VM; Gourgiotis D; Hassiakos D; Malamitsi-Puchner A
    Neonatology; 2010; 97(1):31-5. PubMed ID: 19590243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
    Lapinski TW; Jaroszewicz J; Wiercinska-Drapalo A
    Viral Immunol; 2006; 19(3):570-5. PubMed ID: 16987075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
    Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome.
    Doughty L; Clark RS; Kaplan SS; Sasser H; Carcillo J
    Pediatr Res; 2002 Dec; 52(6):922-7. PubMed ID: 12438671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
    Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
    Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
    Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
    World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease.
    Musiał K; Zwolińska D
    Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBV-DNA and sFas, sFasL concentrations in serum of healthy HBsAg carriers.
    Lapiński TW; Kowalczuk O; Prokopowicz D; Chyczewski L; Jaroszewicz J
    Rocz Akad Med Bialymst; 2005; 50():179-82. PubMed ID: 16358961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.